Breast Cancer Clinical Trials: HR+, HER2+ or Triple-Negative, and Why Subtype Comes First

Breast cancer treatment continues to change as targeted drugs, antibody-drug conjugates, and immunotherapies are studied. A clinical trial is one option to raise with the treating oncologist. It is not automatically better than approved treatment. The useful question is whether a given study matches this subtype, stage, biomarker profile, and treatment history.

HR+, HER2+, and triple negative are not interchangeable

Receptor status decides both standard treatment and which trials fit. A listing written for HER2-positive metastatic disease is not the same as one for HR+/HER2− adjuvant therapy or for triple-negative first-line metastatic disease.

HR+/HER2− disease is usually treated with endocrine therapy, sometimes with targeted drugs added. Many trials in this group test new endocrine partners, CDK4/6 combinations, or PIK3CA-directed treatment when that mutation is present.

HER2-positive disease is treated with HER2-directed drugs. Trials may test new antibodies, conjugates, or combinations in early or metastatic settings.

Triple-negative disease lacks ER, PR, and HER2 targets for routine endocrine or HER2 therapy. Chemotherapy remains central, and immunotherapy is an option in defined TNBC settings, sometimes with a PD-L1 result.

The plain-language clinical trial glossary can help with terms such as eligibility, phase, and standard of care.

Biomarkers that actually separate one trial from another

ER and PR status define HR+ disease. They are checked on every invasive breast cancer and are required for many adjuvant and metastatic protocols.

HER2 testing separates HER2-positive from HER2-negative disease. HER2-low is a separate category in some antibody-drug conjugate trials. It is not the same question as classic HER2-positive disease.

BRCA1 and BRCA2 changes, whether inherited or found only in the tumor, can open trials of PARP inhibitors and other DNA-repair directed treatment. Genetic counseling is often part of that pathway.

PIK3CA mutations appear mainly in HR+ breast cancer and are named in targeted-therapy protocols. ESR1 mutations often emerge after endocrine therapy and can matter in later-line metastatic trials.

PD-L1 is mainly discussed in triple-negative disease for some immunotherapy combinations. A PD-L1 result does not by itself say which studies fit.

Some of these markers have approved treatments in defined settings. Those approvals depend on the exact result, the subtype, prior treatment, the test that was used, and the country where care is given.

Recruiting breast cancer trials

Questions to ask an oncologist

A short list is usually enough:

• What are the ER, PR, and HER2 results, and was HER2-low reported separately?
• Is this HR+/HER2−, HER2-positive, or triple-negative disease?
• Was germline and/or tumor testing done for BRCA1, BRCA2, PIK3CA, and ESR1, and what were the results?
• Is the cancer early stage (including adjuvant or neoadjuvant setting) or metastatic, and which treatments have already been used?
• For this subtype and biomarker profile, what is approved or considered standard where I live?
• Are there recruiting trials that match this exact profile, and how do they differ from standard care?

Want to prepare for the appointment? The guide How to Talk to Your Doctor About Clinical Trials explains how to raise the topic and what to bring with you.

Sources

• NCI: Breast cancer
• NCI PDQ: Breast cancer treatment (patient)
• NCI PDQ: Breast cancer treatment (health professional)
• NCI: Biomarker testing for cancer treatment
• Recruiting-trial facts on this page come from ClinicalTrials.gov and are shown through TrialFinder listings.

This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.